In a large-scale study, researchers have discovered that metformin, a drug typically prescribed for type 2 diabetes, may hold the key to preventing or reducing weight gain in young individuals undergoing treatment for bipolar disorder.

Patients with bipolar disorder often rely on second-generation antipsychotic medications (SGAs) to improve their mental health. However, these medications can bring along a host of side effects, including elevated blood pressure, increased glucose levels, heightened appetite, and weight gain. 

In the study, researchers from the University of Cincinnati (UC) and Northwell Health, New Yorks largest healthcare provider, enrolled 1,565 patients between the ages of 8 and 19. All the participants were diagnosed with bipolar disorder and prescribed SGAs. Notably, 33% of the young participants exhibited signs of metabolic syndrome at the outset.

After prescribing metformin, in the short-term follow-up data, it demonstrated a modest but significant effect in preventing and, in some cases, reversing weight gain in these young patients. Notably, the drug proved to be safe, with the only reported side effects being mild gastrointestinal distress symptoms. 

However, it was also seen that while metformin impacted weight gain, it did not have a significant short-term effect on metabolic syndrome in the youth population.

(Source:https://www.daijiworld.com/news/newsDisplay?newsID=1134776 )